Filtered By:
Specialty: Health Management
Source: The European Journal of Health Economics
Condition: Thrombosis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
ConclusionsHCRU and most event-related costs were lower in patients initiating apixaban compared to other OACs. Apixaban may be cost-saving compared to VKAs, and significantly cheaper than other DOACs, although cost differences are limited.
Source: The European Journal of Health Economics - August 28, 2022 Category: Health Management Source Type: research
